BHVN
Biohaven Ltd (BHVN)
Healthcare • NYSE • $14.08+4.67%
- Symbol
- BHVN
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $14.08
- Daily Change
- +4.67%
- Market Cap
- $2.21B
- Trailing P/E
- N/A
- Forward P/E
- -7.37
- 52W High
- $18.57
- 52W Low
- $7.48
- Analyst Target
- $23.07
- Dividend Yield
- N/A
- Beta
- 3.16
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also devel…
Company websiteResearch BHVN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.